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Inadequate secretion of vasopressin during fluid removal by
hemodialysis may contribute to the cardiovascular instability
that complicates this therapy and administration of
exogenous hormone, by supporting arterial pressure, may
facilitate volume removal. To test this, we measured plasma
vasopressin in patients with end-stage renal disease (ESRD)
during hemodialysis and found that despite significant fluid
removal, plasma vasopressin concentration did not increase.
We further found that ESRD did not alter the endogenous
removal rate of plasma vasopressin and that plasma
hormone is not dialyzed. Finally, in a randomized,
double-blinded, placebo-controlled trial in 22 hypertensive
patients, we examined the effect of a constant infusion of
a non-pressor dose of vasopressin on the arterial pressure
response during a hemodialysis in which the target fluid loss
was increased by 0.5 kg over the baseline prescription. We
found that arterial pressure was more stable in the patients
receiving vasopressin and that while only one patient (9%)
in the vasopressin group had a symptomatic hypotensive
episode, 64% of the patients receiving placebo had such an
episode (P¼ 0.024). Moreover, increased fluid removal was
achieved only in the vasopressin group (520790 ml vs
647130 ml, P¼ 0.01). Thus, administration of non-pressor
doses of vasopressin to hypertensive subjects improves
cardiovascular stability during hemodialysis and allows
increased removal of excess extracellular fluid. Inadequate
vasopressin secretion during hemodialysis-induced fluid
removal is a likely contributor to the intradialytic
hypotension that limits fluid removal.
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In patients with end-stage renal disease (ESRD) treated with
hemodialysis, removal of excess extracellular fluid during the
relatively short period of a typical dialysis session frequently
leads to symptomatic decreases in arterial pressure.1 In
addition to its directly deleterious effects, intradialytic
hypotension and/or attempts to prevent it hinder normal-
ization of the extracellular fluid, leaving many patients
chronically volume-expanded.2 In turn, volume expansion is
a major cause of hypertension in patients on hemodialysis.3–5
As in the general population, hypertension in patients with
ESRD on hemodialysis is associated with high rates of
cardiovascular diseases6–8 and reduced lifespan.9–11 Thus, the
mechanisms of and therapy for intradialytic hypotension are
of great interest.
Fluid removal during hemodialysis fails to elicit the
systemic vasoconstriction expected for acute decreases of
blood volume.12–16 In some forms of hypotension without
appropriate vasoconstriction or with frank vasodilation, we
recently found that the plasma concentration of arginine
vasopressin (vasopressin) was inappropriately low.17,18 In
such conditions, administration of exogenous hormone at
doses that are not pressor in healthy subjects quickly restored
blood pressure. Several reports suggest that volume removal
during hemodialysis does not increase plasma vasopressin in
patients with ESRD19–25 and thus we postulated that non-
pressor doses of exogenous hormone may maintain arterial
pressure during hemodialysis-mediated fluid removal. To test
this hypothesis, we examined the effects of ESRD and of hemo-
dialysis on plasma vasopressin and the effect of hormone
administration on the arterial pressure response to fluid
removal during hemodialysis.
RESULTS
Effect of hemodialysis on the concentration of endogenous
plasma vasopressin
To determine whether routine volume removal during
hemodialysis increased plasma vasopressin, its concentration
was measured in patients with ESRD during a standard
hemodialysis treatment. The average weight of the patients
decreased from 66.675.0 kg before dialysis to 63.675.0 kg
after treatment (Po0.01; n¼ 10), a reduction of 4.5%.
Systolic arterial pressure also decreased during hemodialysis,
averaging 14477 mm Hg at the start of the treatment and
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12377 mm Hg at its completion (Po0.01). Mean plasma
vasopressin concentration was 3.170.7 pg/ml before dialysis;
2.370.8 and 4.171.0 after one- and two-thirds of the
procedure, respectively; and 5.071.5 pg/ml at its conclusion.
Analysis of variance revealed that plasma vasopressin
concentration did not change significantly.
Effect of vasopressin administration on its plasma
concentration in patients with ESRD and controls
To determine whether the disappearance rate of vasopressin
in plasma is altered in renal failure, a constant intravenous
infusion of hormone (0.3 mU kg1 min1) was administered
to healthy control subjects and to patients with ESRD.
Figure 1 shows the mean plasma vasopressin concentrations
as well as the systolic arterial pressures in the two groups of
subjects during infusion of the hormone. Mean vasopressin
plasma concentrations did not differ significantly between
groups. In both normal subjects and in patients with ESRD,
systolic arterial pressure was not significantly changed by the
infusion of vasopressin.
Effect of hemodialysis on plasma vasopressin concentration
during constant infusion of hormone
To determine whether hemodialysis removes vasopressin
from plasma, we examined the effect of the procedure on the
steady-state plasma concentration of hormone during a
constant infusion. To obtain a stable plasma concentration,
vasopressin (0.3 mU kg1 min1) was infused to patients with
ESRD for B1 h prior to hemodiaylsis and the infusion
continued during 2 h of treatment. Mean plasma concentra-
tion of hormone at the start of the treatment was 4776 pg/
ml and it was 5476 pg/ml at 1 h and 5279 pg/ml at 2 h of
dialysis (n¼ 8); analysis of variance showed that hemodia-
lysis had no significant effect on the plasma vasopressin
concentration.
Effect of vasopressin administration during increased
hemodialysis-induced fluid removal
To determine whether exogenous vasopressin may improve
blood pressure stability during hemodialysis-mediated fluid
removal, the hormone was administered during a hemo-
dialysis in which the target for weight reduction was
increased by 0.5 kg beyond the baseline prescription to
‘remove the weight gained since the last treatment.’ On the
day of study, subjects were randomized to receive, in double-
blind fashion, vasopressin (0.3 mU kg1 min1) or placebo
during the dialysis. Table 1 shows the patient characteristics
and important parameters of the dialysis session. The table
also shows that the weight gained since the last treatment
(‘baseline prescription’) and, therefore, the ‘study target fluid
loss’ (baseline prescription plus 0.5 kg) did not differ
significantly between the two groups. The total ultrafiltration
and the weight lost achieved during the hemodialysis were
also similar in the two groups.
The systolic arterial pressure in the two groups of patients
during dialysis (Figure 2) was not significantly different
(Table 2). However, systolic arterial pressure in the group that
received vasopressin was significantly more stable: When
compared to the placebo group, the maximum drop from the
overall systolic pressure was smaller (1672 vs 3475 mm Hg,
P¼ 0.008) and the lowest systolic pressure was higher
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Figure 1 | Infusion of exogenous vasopressin to normal controls
and patients with ESRD. (a) Plasma vasopressin concentrations and
(b) systolic arterial pressure during vasopressin infusion. Vasopressin
was administered to normal subjects (’; n¼ 4) and to patients with
ESRD on a day off dialysis (n¼ 4). (a) Plasma vasopressin significantly
increased in both groups (Po0.001) and there were no significant
differences between them. (b) Systolic arterial pressure was not
significantly changed by vasopressin in controls or patients
with ESRD.
Table 1 | Patient characteristics and dialysis parameters
Placebo
(n=11)
Vasopressin
(n=11)
P-
value
Age (years) 60.872.0 55.172.5 0.09
Gender (female:male) 1:10 2:9 0.56
Patients with diabetes 57% 38% 0.48
Number of antihypertensive
medications/patient
2.570.3 3.170.4 0.33
Weight loss previous six dialysis (kg) 3.070.4 2.970.6 0.82
Baseline prescribed fluid lossa (kg) 2.970.3 2.570.4 0.40
Study target fluid lossb (kg) 3.470.3 3.070.4 0.37
Ultrafiltration achieved (l) 3.170.5 3.070.5 0.21
Weight lost (kg) 3.070.8 3.270.6 0.79
aBaseline prescribed fluid loss was determined by the weight gained since the last
treatment.
bStudy target fluid loss was defined as the baseline prescribed fluid loss plus 0.5 kg.
Kidney International (2007) 71, 318–324 319
S van der Zee et al.: Vasopressin in hemodialysis o r i g i n a l a r t i c l e
(13376 vs 11475, P¼ 0.023). In addition, increasing the
target volume for fluid removal resulted in a symptomatic
hypotensive episode in seven of the 11 patients receiving
placebo but only in one of the eleven patients receiving
vasopressin (64 vs 9%, P¼ 0.024).
In response to arterial pressure changes during dialysis
and patient’s symptoms, the nurse conducting the dialysis
administered to patients in the placebo group 373779 ml of
normal saline for pressure support (P¼ 0.008), but a non-
significant amount of saline to those receiving vasopressin
(45745 ml; P¼ 0.002 vs placebo; Figure 3a).
Finally, while the volume of extra fluid removed during
the dialysis above the baseline prescription was not significant
in the placebo group (647130 ml), patients in the vasopres-
sin group attained the study’s goal for additional fluid
removal (520790 ml; Po0.001; P¼ 0.01 vs placebo; Figure
3b). After the hemodialysis session, all patients were managed
per routine. No patient reported orthostatic symptoms
between the end of the study and the following dialysis.
Arterial pressure after hemodialysis and vasopressin infusion
To examine whether increased fluid removal with vasopressin
would be associated with increased hypotension postdialysis,
arterial pressure was recorded after the treatment in six
hypertensive patients in a crossover trial. Figure 4 shows the
mean arterial pressures during completion of two hemodia-
lysis treatments. In one standard control treatment without
vasopressin, fluid removal was targeted to dry weight. In the
other hemodialysis, vasopressin was infused and additional
fluid was removed, on average 0.5 kg greater than during the
control day. As shown, the lowest mean systolic arterial
pressures during the period of observation were identical
(120 mm Hg) but whereas it occurred at the end of
hemodialysis during the standard treatment, on the day of
vasopressin infusion it occurred 30 min after the treatment, a
time by which most of the exogenous vasopressin in plasma
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Figure 2 | Systolic arterial pressure in patients receiving placebo
(&) or vasopressin (’) during the study dialysis. Systolic arterial
pressures before and during dialysis were not significantly different
between the two groups. As detailed in the text, however, the group
of patients receiving vasopressin had a significantly more stable
arterial pressure during the treatment. N¼ 11 in each group.
Table 2 | Hemodynamic parameters on day of study
Placebo
(n=11)
Vasopressin
(n=11) P
Mean SAP during dialysis (mm Hg) 13674 14676 0.18
Mean hear rate during dialysis (beats/min) 7975 6974 0.16
Maximal SAP drop from mean (mm Hg) 3475 1672 0.008
Lowest SAP (mm Hg) 11475 13376 0.023
Patients with symptomatic hypotensive
episode
64% 9% 0.024
P, P-value; SAP, systolic arterial pressure.
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Figure 4 | Systolic arterial pressure after hemodialysis and
vasopressin infusion. Systolic arterial pressure is shown before
and after termination of hemodialysis during two treatments in six
patients. A control hemodialysis to remove weight gained is
compared to a treatment in which vasopressin was infused and
the fluid removed averaged 0.5 kg above control.
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Figure 3 | Fluid administered and removed during hemodialysis.
(a) Volume administered for pressure support and (b) excess fluid
removed during the study hemodialysis. (a) Patients in the placebo
group received 373779 ml (Po0.01) of normal saline for pressure
support while patients in the vasopressin group received a non-
significant amount of fluid (45745 ml; Po0.01 vs the placebo group).
(b) Whereas the volume of extra fluid removed during the dialysis
above the baseline prescription was not significant in the placebo
group (647130 ml), patients in the vasopressin group had
520790 ml of additional fluid removed (Po0.001; Po0.02 vs
placebo group).
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should be metabolized.15 Only one patient experienced
lightheadedness, once during standard hemodialysis and
once during vasopressin-facilitated fluid removal. Thus,
when compared to a standard hemodialysis, the incidence
of symptomatic hypotension was not increased by greater
fluid removal during hemodialysis with vasopressin.
DISCUSSION
During hemodialysis, excess extracellular fluid is removed
by ultrafiltration until the patient is returned to his or her
‘dry weight.’ However, ‘dry weight’ is empirically assigned to
that weight at which symptomatic decreases in blood
pressure are very likely to occur if further volume is
removed.1,2 Even in the presence of expanded extracellular
fluid volume (i.e., edema), fluid removal by hemodialysis
frequently causes hypotension, a complication that has
beleaguered hemodialysis therapy since its inception.
Thus, paradoxically, to avoid hypotension during hemodia-
lysis, patients at their ‘dry weight’ are often volume
expanded2 and consequently hypertensive between dialysis
treatments.4,5
Reduction of extracellular fluid volume during hemodia-
lysis often fails to elicit the systemic vasoconstriction12–16 that
normally occurs when fluid is removed by ultrafiltration
without hemodialysis.12,14 We recently found that an
important pathogenetic factor in some forms of hypotension
without vasoconstriction is an inappropriately low concen-
tration of plasma vasopressin (reviewed in Landry and
Oliver26). As is well known, in addition to osmolarity, the
secretion of vasopressin is under baroreflex control and
decreases in blood volume activate the baroreflex-triggered
secretion of vasopressin, increasing its plasma concentra-
tion.27 In the setting of a decrease in blood volume,
vasopressin contributes to blood pressure maintenance.28
During a standard hemodialysis treatment, plasma volume
typically decreases 10–20%,23,25 a change that should suffice
to induce vasopressin secretion27 and increase its concentra-
tion in plasma. However, confirming the observations of
others,19–25 we found that volume removal during hemo-
dialysis does not increase plasma vasopressin.
Because the effect of renal failure on the clearance of
plasma vasopressin was unresolved,29,30 we sought to exclude
the possibility that changes in plasma vasopressin during
hemodialysis could be masked by increased hormone
catabolism in renal failure. Thus, we infused vasopressin to
normal subjects and patients with ESRD and followed plasma
levels. We found that the plasma concentrations achieved
were similar in the two groups of subjects, suggesting that
that end-stage renal failure does not significantly alter the
clearance of plasma vasopressin.
Next, we aimed to exclude the possibility that vasopressin
could be removed from plasma by hemodialysis. Hence, we
infused hormone to patients with ESRD and after achieving a
steady plasma concentration, hemodialysis was begun. We
found that hemodialysis did not significantly alter the
concentration of vasopressin. This suggests that vasopressin,
although not protein bound, is nonetheless not effectively
removed by hemodialysis from plasma, likely due to its
molecular weight 41000 Da.
The findings that vasopressin catabolism is not increased
in patients with ESRD and that the hormone is not
significantly lost through the dialysis membrane, led us to
conclude that extracellular fluid removal during hemodialysis
does not increase vasopressin secretion. Several mechanisms
may account for the failure to secrete vasopressin during
hemodialysis-mediated extracellular fluid removal. First of
all, there is a substantial decrease in the plasma osmolarity
during standard hemodialysis31 and it is possible that, in a
reversal of the well documented baroreflex modulation of the
osmotic set-point for vasopressin secretion,27 decreases in
osmolarity could inhibit baroreflex-mediated vasopressin
secretion. However, the rise in plasma vasopressin following
hemorrhage was found to be unaffected by hypo-osmol-
ality.32 Another intriguing possibility is that the increased
nitric oxide synthesis that occurs during hemodialysis33 may
inhibit vasopressin secretion.34 Finally, autonomic dysfunc-
tion due to uremia is frequently listed as a potential cause of
blood pressure instability during hemodialysis1 and it is
possible that it may contribute to the impaired baroreflex-
mediated vasopressin secretion. Additional work is needed to
distinguish between these alternatives.
Of note is that the dose of vasopressin infused in this
study (0.3 mU kg1 min1) increased its plasma concentra-
tion to a steady value of B45 pg/ml but failed to increase
arterial pressure in healthy subjects (as reported pre-
viously35–37) or in patients with ESRD. However, similar
concentrations are seen during modest hemorrhage32 or
hypotension38 and in these circumstances, the hormone
becomes critical for the maintenance of blood pressure.18,28
Hence, we examined whether administration of exogenous
hormone during hemodialysis in patients with ESRD may
prevent development of hypotensive episodes, thus allowing a
more complete correction of their volume expansion. To do
this, we administered vasopressin during a hemodialysis
session in which the amount of fluid to be removed was
increased slightly above the clinically indicated value. In as
much as ESRD patients maintained on hemodialysis who
have an elevated arterial pressure are more likely to have
expansion of the extracellular fluid volume,4,5 patients with
hypertension between dialysis treatments were selected to
examine this hypothesis.
We found that when the amount of extracellular fluid to
be removed by hemodialysis was increased by 17% above the
baseline prescription, vasopressin administration markedly
improved the stability of the systolic arterial pressure when
compared to controls. Patients receiving placebo had
significantly more hypotensive episodes were given greater
amounts of saline by the nurse conducting the treatment and
could not attain the target fluid loss. This suggests that, as
extracellular fluid volume was decreased by dialysis, exogen-
ous vasopressin contributed to the maintenance of their
arterial pressure.
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Taken together, our results suggest that, at least in some
patients, inadequate vasopressin secretion contributes to the
cardiovascular instability that complicates hemodialysis and
that administration of exogenous hormone at doses that do
not raise arterial pressure improves cardiovascular stability
during hemodialysis-induced fluid removal. Hypotension
during hemodialysis may be, like other states of vasodilatory
hypotension, characterized by a deficiency of vasopressin and
exquisite sensitivity to hormone replacement.26 Detailed
studies are required to delineate the etiology of the secretory
defect and the potential contribution of binding proteins to
vasopressin metabolism.
Clinical outcome trials are needed to determine whether
prevention of intradialytic hypotension with vasopressin may
improve chronic control of extracellular fluid volume in
patients with ESRD. This, needless to say, could reduce the
high incidence of hypertension in these patients, a maneuver
with potentially considerable impact on their cardiovascular
morbidity6–8 and lifespan.9–11 Of note, recent studies suggest
that decreasing the rate of fluid removal by extending the
duration of hemodialysis improves hemodynamic stability
and diminishes chronic hypertension, likely because extra-
cellular fluid volume is better controlled.39,40 Replacement
with non-pressor doses of vasopressin during hemodialysis
may provide an additional therapeutic tool to attain this goal.
MATERIALS AND METHODS
Patients
Studies were performed at the Acute Dialysis Unit of the New York
Presbyterian Hospital and at the Columbia University Dialysis
Center, both located at Columbia University Medical Center. All
patients gave informed consent to participate in the studies, which
were approved by the Institutional Review Board of Columbia
University. The study adhered to the Declaration of the Helsinki
Principles.
For all studies, except when indicated in the specific protocols,
any patient that had ESRD and was maintained on hemodialysis was
a candidate for study. Exclusion criteria for all patients were as
follows: (1) active vascular disease, including angina, claudication,
transient ischemic events, ischemic colitis, and Raynaud’s disease;
(2) a history of prolonged QT syndrome; (3) a history of orthostatic
hypotension or frequent episodes of intra-dialytic hypotension; (4) a
systolic blood pressure greater than 200 mm Hg and/or a diastolic
blood pressure greater than 100 mm Hg; and (5) a history of, or
clinical evidence of, congestive heart failure.
All patients were studied at regularly scheduled dialysis sessions
and all management decisions were left to the health care personnel
managing the treatment. Patients underwent conventional hemo-
dialysis with hollow fiber high flux polysulfone dialyzers on
volumetric dialysis machines (Cobe Centrysystem 3, Gambro Renal
Care Products, Inc., Lakewood, CO, USA). Dialysis time was B4 h.
Blood flow was 300–400 ml/min and dialysate was delivered at
600 ml/min. The dialysis bath contained potassium, 2 mEq/l;
calcium, 2.5 mEq/l; magnesium, 0.75 mEq/l; and bicarbonate,
40 mEq/l. In those patients who were prescribed dialysate sodium
modeling and/or reduced dialysate temperature (35–371C) prior to
the study, the parameters of these interventions were held constant
throughout the study. Ultrafiltration was performed at a constant
rate based on the target weight loss for that dialysis session.
Oscillometric blood pressure and heart rate measurements were
taken at 15–30 min intervals per routine at the dialysis center.
Plasma vasopressin concentration
Vasopressin in plasma was determined as previously described.17
Study protocols
Effect of hemodialysis on the concentration of endogenous
plasma vasopressin. Ten patients with ESRD had samples of
venous blood collected during a standard hemodialysis treatment
for determination of plasma vasopressin. Vasopressin was measured
before starting the treatment, twice during it and at its conclusion.
Effect of vasopressin administration on its plasma
concentration in patients with ESRD and in controls. Because
the effect of exogenous vasopressin on the arterial pressure of
patients with ESRD was unknown and these patients are frequently
afflicted with hypertension, in addition to the exclusion criteria
detailed above, subjects selected for this protocol were required to
have a normal arterial pressure (o140 mm Hg systolic pressure).
Four healthy normal volunteers and four patients with ESRD
maintained on hemodialysis received an infusion of vasopressin
while blood samples were collected for determination of the
hormone concentration in plasma. 8-arginine vasopressin (Amer-
ican Pharmaceutical Partners, Schaumberg, IL, USA) in normal
saline was administered through an antecubital intravenous line at a
rate of 0.3 mU kg1 min1 for 2 h.
Effect of hemodialysis on plasma vasopressin concentration
during constant infusion of hormone. Eight patients with ESRD
received an intravenous infusion of vasopressin (of
0.3 mU kg1 min1) begun B1 h prior the start of a routine
hemodialysis and continued during the first 2 h of treatment. Blood
samples were collected for determination of vasopressin in plasma at
the beginning and after 1 and 2 h of dialysis.
Effect of vasopressin administration during increased
hemodialysis-induced fluid removal. A unique group of 22
patients with ESRD was selected to study the effect on the arterial
pressure of an infusion of vasopressin during a hemodialysis
treatment during which the target weight reduction specified by the
standard dialysis prescription – to remove the weight gained – was
increased by 0.5 kg. In addition to the exclusion criteria detailed
above for all patients, subjects included in this protocol had the
following additional inclusion criteria: (a) hypertension (defined by
a systolic arterial pressure greater than 140 mm Hg or a requirement
for antihypertensive medications to maintain a lower systolic arterial
pressure); (b) no hypotensive episode during the three hemodialysis
treatments of the week preceding the study; and (c) the predialysis
weight on the day of study within 71 kg of the mean predialysis
weight of the previous three sessions. Patients were studied 2 days
after the previous dialysis, a requirement that excluded the first
hemodialysis treatment following the week-end.
The protocol was a randomized, double-blinded, placebo-contro-
lled trial comparing the effect of vasopressin (0.3 mU kg1 min1)
in normal saline vs the same volume of normal saline alone
on the incidence and magnitude of systolic hypotension and
hypotensive symptoms elicited by the 0.5 kg increase in weight
reduction. The infusion solutions were prepared by a researcher
uninvolved with the hemodialysis treatment and patient care. The
solutions were physically indistinguishable and the nurse conducting
the dialysis, although aware of the study, was blinded to the
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intervention. Otherwise, the hemodialysis routine was unchanged
and managed exclusively by the health care personnel performing
the treatment. Symptomatic hypotension was identified by the nurse
conducting the dialysis treatment (criteria included a sudden drop
in systolic arterial pressure associated with one or more of the
following: lightheadedness, dizziness, cramping, nausea, and vomit-
ing) and managed per routine with administration of normal saline
and/or a decrease in ultrafiltration rate.
Arterial pressure after hemodialysis. To ascertain the arterial
pressure response after the completion of hemodialysis and the
discontinuation of the vasopressin infusion, six patients with
hypertension as defined above were provided with ambulatory
blood pressure monitors (Spacelabs, model 90217) and instructed to
maintain their usual routine while wearing the pressure monitor for
up to 4 h posthemodialysis. In a non-blinded crossover design,
arterial pressure was recorded after two hemodialysis treatments
with starting treatment assignment randomized to avoid an order
effect. In a standard treatment, fluid removal was prescribed to be
the targeted dry weight (as defined above). In the other
hemodialysis, vasopressin was infused (0.3 mU kg1 min1) and
additional fluid removed averaged 0.5 kg beyond the control day
fluid removal.
Statistical analyses
Analyses were performed using Statistical Package for the Social
Sciences, version 12.0. Comparisons between treatment arms were
made by independent samples t-test. Analysis of time trends for
continuous variables was performed using analysis of variance. All
values are expressed as mean7s.e. unless otherwise stated. P-values
of less than 0.05 (two-tailed) were considered statistically significant.
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